Wed, September 4, 2024
Fri, May 31, 2024
[ 12:00 AM ] - WOPRAI
Tue, June 6, 2023
[ 12:00 AM ] - WOPRAI
Thu, May 25, 2023
[ 12:00 AM ] - WOPRAI
Thu, March 30, 2023
[ 12:00 AM ] - WOPRAI
Tue, March 28, 2023
[ 12:00 AM ] - WOPRAI
Mon, March 20, 2023
[ 12:00 AM ] - WOPRAI
Thu, March 2, 2023
[ 12:00 AM ] - WOPRAI
Tue, December 20, 2022
[ 12:00 AM ] - WOPRAI
Fri, December 2, 2022
[ 12:00 AM ] - WOPRAI
Wed, October 5, 2022
[ 12:00 AM ] - WOPRAI
Fri, September 9, 2022
[ 12:00 AM ] - WOPRAI
Fri, July 15, 2022
[ 12:00 AM ] - WOPRAI
Tue, May 10, 2022
[ 12:00 AM ] - WOPRAI
Fri, March 26, 2021
[ 12:00 AM ] - WOPRAI
Wed, February 3, 2021
Mon, January 11, 2021
[ 12:00 AM ] - WOPRAI
Thu, February 21, 2019
[ 12:00 AM ] - WOPRAI
Tue, August 7, 2018
[ 12:00 AM ] - WOPRAI
Tue, October 17, 2017
Fri, June 30, 2017
Mon, May 22, 2017
Thomas Shrader Downgraded (ATHA) to Hold on, Sep 4th, 2024
Thomas Shrader of BTIG, Downgraded "Athira Pharma, Inc." (ATHA) to Hold on, Sep 4th, 2024.
Thomas has made no other calls on ATHA in the last 4 months.
There is 1 other peer that has a rating on ATHA. Out of the 1 peers that are also analyzing ATHA, 0 agree with Thomas's Rating of Hold.
This is the rating of the analyst that currently disagrees with Thomas
- Elemer Piros of "Rodman & Renshaw" Initiated at Strong Buy and Held Target at $22 on, Monday, August 19th, 2024
Contributing Sources